©TheCanadian Journal ofUrology™: International Supplement, April 2014
13
TilkiANDEvans
59.GleaveM, TolcherA,MiyakeH et al. Progression toandrogen
independence isdelayedbyadjuvant treatmentwithantisense
Bcl-2 oligodeoxynucleotides after castration in the LNCaP
prostate tumormodel.
ClinCancerRes
1999;5(10):2891-2898.
60.LiuAY,CoreyE,BladouF,LangePH,VessellaRL.Prostaticcell
lineagemarkers: emergenceof BCL2+ cells of humanprostate
cancerxenograftLuCaP23followingcastration.
IntJCancer
1996;
65(1):85-89.
61.McDonnell TJ, TroncosoP, Brisbay SM et al. Expressionof the
protooncogene bcl-2 in the prostate and its association with
emergenceofandrogen-independentprostatecancer.
CancerRes
1992;52(24):6940-6944.
62.BrandLJ,DehmSM.Androgen receptorgene rearrangements:
new perspectives on prostate cancer progression.
Curr Drug
Targets
2013;14(4):441-449.
63.MacVicarGR, HussainMH. Emerging therapies inmetastatic
castration-sensitive and castration-resistant prostate cancer.
CurrOpinOncol
2013;25(3):252-260.
64.Rathkopf D, Scher HI. Androgen receptor antagonists in
castration-resistant prostate cancer.
Cancer J
2013;19(1):43-49.
65.Sharifi N. Minireview: Androgen metabolism in castration-
resistant prostate cancer.
Mol Endocrinol
2013;27(5):708-14.
66.HornbergE,YlitaloEB,CrnalicSet al. Expressionof androgen
receptor splice variants in prostate cancer bone metastases
is associated with castration-resistance and short survival.
PLoSOne
2011;6(4):e19059.
67.SadarMD.Smallmolecule inhibitorstargetingthe“achilles’heel”
of androgen receptor activity.
CancerRes
2011;71(4):1208-1213.
68.AndersenRJ,Mawji NR,Wang J et al. Regression of castrate-
recurrent prostate cancer by a small-molecule inhibitor of the
amino-terminus domain of the androgen receptor.
Cancer Cell
2010;17(6):535-546.
69.Yang L, LinC, JinC et al. lncRNA-dependentmechanisms of
androgen-receptor-regulatedgeneactivationprograms.
Nature
2013:500(7464):598-602.
70.Bui M, Reiter RE. Stem cell genes in androgen-independent
prostate cancer.
CancerMetastasisRev
1998;17(4):391-399.
71. Isaacs JT. The biology of hormone refractory prostate cancer.
Whydoes it develop?
Urol ClinNorthAm
1999;26(2):263-273.
72.LockeJA,GunsES,LehmanMLetal.Arachidonicacidactivation
of intratumoral steroid synthesis during prostate cancer
progression tocastrationresistance.
Prostate
2010;70(3):239-351.
73.Lubik AA, Gunter JH, Hendy SC et al. Insulin increases de
novo steroidogenesis in prostate cancer cells.
Cancer Res
2011;71(17):5754-5764.
74.MontgomeryRB,Mostaghel EA,VessellaR et al.Maintenance
of intratumoral androgens in metastatic prostate cancer: a
mechanismforcastration-resistanttumorgrowth.
CancerRes
2008;
68(11):4447-4454.
75.Locke JA, Guns ES, LubikAA et al. Androgen levels increase
by intratumoral de novo steroidogenesis during progression
of castration-resistant prostate cancer.
Cancer Res
2008;68(15):
6407-6415.
